Description

Encicarb 500mg Injection: A Comprehensive Overview

Encicarb 500mg Injection contains Ferric Carboxymaltose, a modern, high-dose intravenous (IV) iron formulation. Doctors use this injection to treat iron deficiency anemia (IDA) in adult patients, particularly when oral iron supplements are ineffective, poorly tolerated, or cannot be administered. It is commonly used in individuals with chronic kidney disease (CKD), including those undergoing dialysis, as well as in other conditions causing significant iron depletion (e.g., inflammatory bowel disease, heavy uterine bleeding).

Mechanism of Action and Therapeutic Protocols

Ferric Carboxymaltose is a non-dextran iron complex consisting of a ferric hydroxide core stabilized by a carbohydrate shell (carboxymaltose). This structure ensures the iron is released in a slow, controlled manner within the reticuloendothelial system. This unique mechanism allows for the administration of a large, high dose of iron in a single or few sessions with minimal risk of releasing large amounts of toxic ionic iron into the serum. Ultimately, this iron is delivered to iron-binding proteins like ferritin (for storage) and transferrin (for transport to the bone marrow), effectively replenishing iron stores and directly supporting the production of red blood cells (hemoglobin synthesis). The controlled delivery and high stability of the complex contribute to its quick and effective correction of iron deficiency.

The injection is administered intravenously under medical supervision, often over a short infusion time, and typically requires fewer total doses compared to older IV iron therapies. The dosage is calculated based on the patient’s body weight and baseline hemoglobin/ferritin levels.

Manufacturing, Safety, and Monitoring

Emcure Pharmaceuticals manufactures Encicarb 500mg Injection.

While generally well-tolerated, a patient should be aware of potential side effects. Common adverse effects may include nausea, headache, flushing, dizziness, elevated blood pressure (hypertension), and injection or infusion site reactions. A potentially serious, though uncommon, side effect is a transient decrease in blood phosphate levels (hypophosphatemia).

For safety, the following monitoring is essential:

• Hypersensitivity: The patient must be monitored closely for at least 30 minutes after each administration for signs of allergic reactions.

• Blood Pressure: Continuous monitoring of blood pressure is recommended during administration.

• Iron Status: Hemoglobin, serum ferritin, and transferrin saturation levels are checked at intervals (e.g., 4 weeks after the final injection) to assess the therapeutic response.

Availability & Purchase Information

Genetec Lifesciences makes Encicarb Ferric Carboxymaltose 500mg Injection available. All medicines are sourced directly from Emcure or its authorized vendors.

Disclaimer

This site provides product information for informative purposes only. The product image belongs to its respective company. Genetec Lifesciences acts as a wholesaler and distributor, not a manufacturer. We source our medicines directly from the company or its authorized vendors.